Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

London-based megabank HSBC may be recognizable to some U.S. consumers, but elsewhere, it is a well-known name that provides ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.